Paradigm Biopharmaceuticals Ltd (PAR) - Net Assets

Latest as of June 2025: AU$21.18 Million AUD ≈ $14.99 Million USD

Based on the latest financial reports, Paradigm Biopharmaceuticals Ltd (PAR) has net assets worth AU$21.18 Million AUD (≈ $14.99 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$24.57 Million ≈ $17.39 Million USD) and total liabilities (AU$3.39 Million ≈ $2.40 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Paradigm Biopharmaceuticals Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$21.18 Million
% of Total Assets	86.21%
Annual Growth Rate	N/A
5-Year Change	-72.94%
10-Year Change	88.64%
Growth Volatility	154.5

Paradigm Biopharmaceuticals Ltd - Net Assets Trend (2014–2025)

This chart illustrates how Paradigm Biopharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Paradigm Biopharmaceuticals Ltd for the complete picture of this company's asset base.

Annual Net Assets for Paradigm Biopharmaceuticals Ltd (2014–2025)

The table below shows the annual net assets of Paradigm Biopharmaceuticals Ltd from 2014 to 2025. For live valuation and market cap data, see PAR market cap.

Year	Net Assets	Change
2025-06-30	AU$21.18 Million ≈ $14.99 Million	-11.01%
2024-06-30	AU$23.81 Million ≈ $16.84 Million	-55.65%
2023-06-30	AU$53.68 Million ≈ $37.98 Million	+26.86%
2022-06-30	AU$42.31 Million ≈ $29.94 Million	-45.94%
2021-06-30	AU$78.27 Million ≈ $55.38 Million	-27.65%
2020-06-30	AU$108.18 Million ≈ $76.55 Million	+30.64%
2019-06-30	AU$82.81 Million ≈ $58.59 Million	+497.27%
2018-06-30	AU$13.86 Million ≈ $9.81 Million	+3.54%
2017-06-30	AU$13.39 Million ≈ $9.47 Million	+19.23%
2016-06-30	AU$11.23 Million ≈ $7.95 Million	-22.36%
2015-06-30	AU$14.46 Million ≈ $10.23 Million	+9624.42%
2014-06-30	AU$-151.87K ≈ $-107.45K	--

Equity Component Analysis

This analysis shows how different components contribute to Paradigm Biopharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 23579711100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component	Amount	Percentage
Common Stock	AU$253.23 Million	1195.39%
Other Comprehensive Income	AU$3.90 Million	18.41%
Total Equity	AU$21.18 Million	100.00%

Paradigm Biopharmaceuticals Ltd Competitors by Market Cap

The table below lists competitors of Paradigm Biopharmaceuticals Ltd ranked by their market capitalization.

Company	Market Cap
Upsales Technology AB ST:UPSALE	$52.19 Million
DIC India Limited NSE:DICIND	$52.22 Million
Accuray Incorporated NASDAQ:ARAY	$52.23 Million
Do Day Dream Public Company Limited BK:DDD	$52.26 Million
Decibel Cannabis Company Inc V:DB	$52.16 Million
Ultimovacs ASA OL:ULTI	$52.14 Million
Cato Corporation NYSE:CATO	$52.13 Million
Korea Electronic Certification Authority Inc KQ:041460	$52.10 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Paradigm Biopharmaceuticals Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 23,806,097 to 21,184,037, a change of -2,622,060 (-11.0%).
Net loss of 18,770,745 reduced equity.
Share repurchases of 16,001,170 reduced equity.
Other comprehensive income decreased equity by 2,522,127.
Other factors increased equity by 34,671,982.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	AU$-18.77 Million	-88.61%
Share Repurchases	AU$16.00 Million	-75.53%
Other Comprehensive Income	AU$-2.52 Million	-11.91%
Other Changes	AU$34.67 Million	+163.67%
Total Change	AU$-	-11.01%

Book Value vs Market Value Analysis

This analysis compares Paradigm Biopharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.52x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2014-06-30	AU$-0.01	AU$0.17	x
2015-06-30	AU$0.44	AU$0.17	x
2016-06-30	AU$0.13	AU$0.17	x
2017-06-30	AU$0.13	AU$0.17	x
2018-06-30	AU$0.12	AU$0.17	x
2019-06-30	AU$0.58	AU$0.17	x
2020-06-30	AU$0.52	AU$0.17	x
2021-06-30	AU$0.37	AU$0.17	x
2022-06-30	AU$0.17	AU$0.17	x
2023-06-30	AU$0.19	AU$0.17	x
2024-06-30	AU$0.08	AU$0.17	x
2025-06-30	AU$0.07	AU$0.17	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Paradigm Biopharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -88.61%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -36014.48%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.16x
Recent ROE (-88.61%) is below the historical average (-59.33%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	0.00%	0.00%	0.00x	0.00x	AU$-215.81K
2015	-10.82%	-21350.61%	0.00x	1.04x	AU$-3.01 Million
2016	-26.04%	-226.56%	0.10x	1.10x	AU$-4.05 Million
2017	-31.93%	-234.50%	0.13x	1.07x	AU$-5.61 Million
2018	-44.65%	-230.71%	0.18x	1.10x	AU$-7.58 Million
2019	-18.87%	-523.73%	0.03x	1.03x	AU$-23.91 Million
2020	-11.37%	-261.93%	0.04x	1.04x	AU$-23.12 Million
2021	-43.82%	-166895.38%	0.00x	1.08x	AU$-42.12 Million
2022	-92.76%	-49543.07%	0.00x	1.20x	AU$-43.48 Million
2023	-96.71%	-111013.71%	0.00x	1.25x	AU$-57.28 Million
2024	-246.38%	-89138.30%	0.00x	1.15x	AU$-61.03 Million
2025	-88.61%	-36014.48%	0.00x	1.16x	AU$-20.89 Million

Industry Comparison

This section compares Paradigm Biopharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $9,810,720
Average return on equity (ROE) among peers: -71.07%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Paradigm Biopharmaceuticals Ltd (PAR)	AU$21.18 Million	0.00%	0.16x	$52.17 Million
Adalta Ltd (1AD)	$3.70 Million	-162.25%	0.87x	$6.50 Million
Algorae Pharmaceuticals Ltd (1AI)	$-1.33 Million	0.00%	0.00x	$20.04 Million
ACRUX Ltd (ACR)	$12.85 Million	-73.71%	0.44x	$3.20 Million
Actinogen Medical Ltd (ACW)	$21.74 Million	-43.69%	0.07x	$105.70 Million
Argenica Therapeutics Ltd (AGN)	$13.95 Million	-39.28%	0.17x	$15.45 Million
Arovella Therapeutics Ltd (ALA)	$11.03 Million	-40.87%	0.23x	$58.08 Million
Anatara Lifesciences Ltd (ANR)	$924.54K	-218.83%	0.54x	$1.57 Million
Alterity Therapeutics Ltd (ATH)	$20.73 Million	-6.40%	0.01x	$76.95 Million
Amplia Therapeutics Ltd (ATX)	$11.23 Million	-30.16%	0.02x	$50.82 Million
Avecho Biotechnology Ltd (AVE)	$3.27 Million	-95.48%	0.53x	$28.59 Million

About Paradigm Biopharmaceuticals Ltd

AU:PAR Australia Biotechnology

Market Cap

$52.17 Million

AU$73.73 Million AUD

Market Cap Rank

#21738 Global

#778 in Australia

Share Price

AU$0.17

Change (1 day)

+3.03%

52-Week Range

AU$0.16 - AU$0.47

All Time High

AU$4.35